2025-11-23 - Analysis Report
Okay, here's an analysis of Tempus AI Inc. (TEM) based on the data you provided, with a focus on numerical summaries, relative performance, recent price action, indicators, news, and analyst opinions:

**Tempus AI Inc. (TEM) Analysis**

**0. Overview**

*   **Ticker:** TEM
*   **Company Description:** Tempus AI Inc. is a technology company that focuses on precision medicine through data analysis and AI.

**1. Performance vs. S&P 500 (VOO)**

*   **TEM Cumulative Return:** 36.54%
*   **VOO Cumulative Return:** 23.94%
*   **Absolute Divergence (TEM - VOO):** 12.60% (TEM outperformed VOO by 12.60% cumulatively.)
*   **Divergence Range:**
    *   Max Divergence: 74.4
    *   Min Divergence: -40.5
    *   Current Divergence: 8.2
    *   Relative Divergence: 42.4 (Indicates the current divergence is in the lower end of its historical range relative to the S&P 500).

**Analysis of Provided Table:**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2023-2025  | 37.0%  | 76.7%  | 14.0%  | 0.3  | 12.5   |

*   **CAGR (Compound Annual Growth Rate):** 37.0% suggests high growth potential over the period.
*   **MDD (Maximum Drawdown):** 76.7% indicates significant volatility and risk.
*   **Alpha:** 14.0% implies outperformance compared to its benchmark, independent of market movements.
*   **Beta:** 0.3 suggests the stock is significantly less volatile than the market.
*   **Cap(B):** $12.5 billion Market Cap

**2. Recent Price Action**

*   **Current Price:** $70.29
*   **Previous Close:** $65.69
*   **Change:** +7.0% (Significantly higher than the previous day's close, suggesting a strong positive price movement.)
*   **Moving Averages:**
    *   5-day MA: $67.65
    *   20-day MA: $76.56
    *   60-day MA: $83.00

**3. Technical Indicators & Outlook**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 23.48 (Oversold - potential for a rebound)
*   **PPO:** -0.95 (Below zero - short term downtrend)
*   **Hybrid Signal:** cash_79%_Sell (Suggests selling 79.9% of holdings due to risk, while increasing cash to 79% of portfolio. Risky - MRI:0.50)
*   **Delta_Previous_Relative_Divergence (20-day):** -1.1 (Negative indicates a short-term decline in relative performance)
*   **Expected Return (%):** NaN (Data not available)

**Significant Price Change:** The +7.0% change from the previous close is a notable event, signaling a potential short-term reversal or continuation of a positive trend. It is important to assess the reasons behind this movement (news, market sentiment, etc.).

**4. Recent News & Significant Events**

*   **Piper Sandler Conference:** Participation in the conference can increase visibility and potentially attract investors.
*   **Earnings Surge and Lymphoma Research:** Positive investor reaction to earnings and the lymphoma research partnership are favorable signs.
*   **Alphabet's Portfolio:** Inclusion in Alphabet's secret portfolio can increase investor confidence.
*   **Follicular Lymphoma Research:** Collaboration with IFLI can potentially improve company image.
*   **Genomics Leadership:** Strengthening genomics leadership with new products can increase investor confidence.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.14)
*   **Number of Opinions:** 12
*   **Target Price:**
    *   Average: $90.25
    *   High: $100.00
    *   Low: $80.00
*   **Recent Rating Changes:** Not available

**5. Overall Assessment**

Based on the provided information:

*   **Strengths:**
    *   Historical outperformance of S&P 500
    *   High CAGR (2023-2025)
    *   Positive Alpha
    *   Analyst consensus indicates "Buy"
    *   Positive news flow regarding research partnerships, earnings, and potential interest from major investors
*   **Weaknesses/Risks:**
    *   Very High MDD, indicating high volatility.
    *   The RSI indicates that it is oversold
    *   Current Relative Divergence is relatively low.
    *   Recent short-term decline in relative performance (Delta_Previous_Relative_Divergence is negative).
    *   Hybrid signal suggests selling due to perceived risk, while increasing cash to 79% of portfolio.

**Conclusion:**

TEM demonstrates strong growth potential and has historically outperformed the S&P 500. However, it exhibits significant volatility, as indicated by the high MDD. The recent price surge suggests positive momentum. The analyst consensus leans towards a "Buy" rating with a significant upside potential based on the average target price.

**Recommendation:**

Given the high volatility and mixed signals (oversold RSI, negative PPO), potential investors should exercise caution. Further research into the reasons behind the recent price surge and the sustainability of the company's growth is warranted. The news flow is generally positive, supporting a bullish outlook, but risk management is crucial. A small allocation might be considered if the investor has a high risk tolerance and believes in the company's long-term prospects.
